GLP-1 Drugs for Obesity: How to Switch From the Needle to a Pill

Now that two oral glucagon-like peptide-1 (GLP-1) receptor agonist medications are approved by the U.S. Food and Drug Administration (FDA) — the semaglutide pill (Wegovy) and orforglipron (Foundayo) — some people are considering making the switch from injectables. GLP-1 pills can not only feel more comfortable and convenient to use than injectable GLP-1s, but they may also be a more affordable option for some.

If you’re switching GLP-1 drugs, it can be difficult to come by straightforward advice on how to manage the transition. Here’s what obesity medicine physicians want you to keep in mind to ensure success.

How to Switch Semaglutides

Injectable Wegovy is available in weekly doses of:

• 0.25 milligrams (mg)
• 0.5 mg
• 1 mg
• 1.7 mg
• 2.4 mg
• 7.2 mg (Wegovy HD)

Wegovy tablets, on the other hand, are available in daily doses of:

• 1.5 mg
• 4 mg
• 9 mg
• 25 mg

Unfortunately, there isn’t an official dose conversion between these two forms of semaglutide.

“There’s no defined or accepted ‘equivalence chart’ when switching from injections to tablets or vice versa,” says Eric Nolen-Doerr, MD, an endocrinologist and weight management specialist at Boston Medical Center in Massachusetts. The dose that you begin with when switching medications is based on a decision between you and your doctor, he says. “[It] will probably be dictated by [your experience] of side effects when taking the injectable form.”

For example, if you haven’t had side effects on an injection, Dr. Nolen-Doerr says he may recommend moving to a higher dose of the oral medication. Conversely, if you’ve experienced a lot of side effects on injectable semaglutide, he may underestimate your needs to play it safe. “I would be less aggressive and ‘undershoot’ my best guess at equivalency,” he says.

When making the switch, Atlanta-based Reema Dbouk, MD, FACP, a spokesperson for The Obesity Society, advises starting your oral medication one week after your last injection of semaglutide.

How to Switch When Starting a New Drug

If you’re moving from injectable tirzepatide (Zepbound) to the semaglutide pill or orforglipron, the equivalent dose is even less clear because not only are you switching drug forms, you’re taking an entirely new drug.

There isn’t official guidance here either. As with injectable semaglutide, the decision is based on your physician’s knowledge of your response to the drug you’re currently taking.

“The exact dose equivalences are not known, but patients should work with their healthcare provider to determine the best dose, taking into account how well they’re tolerating their GLP-1 injection,” says Dr. Dbouk.

Your physician can also use a titration schedule to help make this decision. For example, if you’re on the second-highest available dose of an injectable GLP-1, then it may be reasonable to start with the comparable dose of the pill, says Dhvani Doshi, MD, MPH, medical director and obesity medicine physician at University Hospital in Newark, New Jersey. To make sure you tolerate it well, however, Dr. Doshi may begin with a lower dose and increase from there.

Just like if you’re switching from injectable semaglutide, Dbouk advises starting oral semaglutide or orforglipron one week after your final tirzepatide injection.

Managing the Transition

To help ensure a successful adjustment from an injectable GLP-1 to oral semaglutide, be prepared to navigate changes in side effects, fluctuations in medication effectiveness, and the practical differences of taking a daily pill versus administering a weekly injection.

First, consider how things may change for you in terms of the habit of taking the medication.

“The main thing I counsel patients about right now is that although it seems as if a daily oral pill is easier, sometimes it’s easier to use an injection once a week,” says Doshi.

After making the transition, Dbouk recommends monitoring yourself for two things: new or worsening side effects and what’s happening to your weight.

Nolen-Doerr says you also may notice the scale move up again when you make the switch to an oral GLP-1. “It really depends on what injectable option we are transitioning from, but generally, or in most cases, I’d expect increased hunger and some weight [regain],” he says. This may be especially likely if you are transitioning off tirzepatide, the most powerful obesity treatment on the market, or have stepped down to a lower dose in order to reduce the risk of side effects.

The Takeaway

• The FDA has approved two oral versions of GLP-1 medications, including semaglutide (Wegovy) tablets and orforglipron (Foundayo), offering a needle-free and potentially more affordable alternative to weekly injections.
• Because there isn’t an official dose equivalency chart for GLP-1 injectables and pills, your doctor will determine your starting dose for an oral medication based on your previous experience with an injectable, including side effects and drug tolerability.
• To be safe, individuals switching to oral GLP-1s should monitor themselves for increased side effects and potential weight regain.